title: Quality of life research: adding an important dimension to the evaluation of therapeutic outcomes.
authors.affiliation: Keck School of Medicine, University of Southern California, Los Angeles, CA 90089-9175, USA. ahamilt@usc.edu
authors.forename: Ann S
authors.initials: AS
authors.lastname: Hamilton
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D035843:Biomedical Research / Q000379:methods* / Q000639:trends; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005069:Evaluation Studies as Topic; D006304:Health Status; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy; D017063:Outcome Assessment, Health Care / Q000379:methods* / Q000639:trends*; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011788:Quality of Life; D000069283:Rituximab; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone